Related Experiment Video

Updated: Aug 23, 2026

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
09:12

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates

Published on: January 30, 2014

Microglial advances in Parkinson's disease

Manuel Debasa-Mouce1, Alberto Ouro2, Joshua De Leon3

  • 1NeuroAging Group (NEURAL), Clinical Neurosciences Research Laboratory (LINC), Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

Advances in Immunology
|August 21, 2026
PubMed

Insights

Microglia, the brain's immune cells, become detrimental in Parkinson's disease (PD) by damaging neurons. Targeting neuroinflammation and enhancing cellular cleanup are key therapeutic strategies for PD.

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Microglia are the central nervous system (CNS) macrophages responsible for immune surveillance and homeostasis.
  • In Parkinson's disease (PD), microglia transition from neuroprotective to neurotoxic roles, contributing to dopaminergic neuron degeneration.
  • This pathological shift is influenced by genetic factors (e.g., LRRK2, GBA mutations) and environmental triggers (e.g., toxins, gut dysbiosis).

Purpose of the Study:

  • To elucidate the mechanisms by which microglia contribute to Parkinson's disease pathogenesis.
  • To identify therapeutic targets for mitigating microglial-driven neuroinflammation and neurodegeneration in PD.
  • To highlight the role of advanced biomarkers and neuroimaging in early PD detection and personalized treatment.

Main Methods:

  • Analysis of microglial activation pathways, including Toll-like receptor (TLR) signaling and α-synuclein interactions.
  • Investigation of the impact of aggregated α-synuclein on microglial endolysosomal function and lysosomal failure.
  • Review of emerging therapeutic strategies such as NLRP3 inflammasome inhibition and autophagy enhancement.
  • Evaluation of advanced diagnostic tools including seed amplification assays (SAA) and multimodal neuroimaging (PET, SPECT, MRI).

Main Results:

  • Extracellular α-synuclein acts as a danger signal, activating microglial TLR2 and initiating inflammatory cascades.
  • Aggregated α-synuclein causes lysosomal failure and 'frustrated phagocytosis,' promoting disease propagation via exosomal shedding.
  • Chronic neuroinflammation driven by microglia is a central pathological feature of Parkinson's disease.

Conclusions:

  • Modulating microglial activity and neuroinflammation is a critical therapeutic avenue for Parkinson's disease.
  • Interventions targeting NLRP3 inflammasome and enhancing autophagy show promise for breaking the disease cycle.
  • Early detection of microglial and pathological changes using fluid biomarkers and advanced neuroimaging is essential for guiding personalized, disease-modifying therapies in PD.
Keywords:
Alpha-synucleinBiomarkersMicrogliaNeuroinflammationParkinson diseaseTherapeutics

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.